• AG1’s diverse team of clinicians, researchers, and PhDs work together to build initial studies.
• The team conducted pre-clinical trials to inform the clinical trials. Pre-clinical studies were intentionally conducted to better understand the biological activity and mechanisms of AG1 Next Gen — an approach that’s both common and foundational in the development of nutrition research. These early insights help inform the design of human clinical trials, enhancing scientific rigor and ensuring that future studies are strategically and effectively guided. Pre-clinical trials and their results can take upwards of 8-10 months to design, implement and analyze the results.
• We then partnered with independent contract research organizations (CROs) and academic institutions to ensure data collection and analysis were objective and professionally managed.
• To ensure scientific integrity and ethical compliance, each human study protocol was submitted for review and approval by an independent Institutional Review Board (IRB) prior to participant recruitment. IRB approval is a critical regulatory step that ensures the rights, safety, and well-being of study participants are protected, and that the research is conducted according to Good Clinical Practice (GCP) and applicable regulations. No human study began without formal IRB approval.
• We then created detailed protocols with third-party scientists (also known as principal scientists) outlining specific criteria including the study population, endpoints, duration, measurements, and statistical plan. The research partners then recruited participants according to inclusion and exclusion criteria outlined in each of the individual study designs to ensure the most objective outcome for each study. Participants and the third-party researchers in the trials were “blinded,” meaning they did not know whether they were taking AG1 or a placebo. As part of the study design, our scientists and statisticians run a power calculation to determine how many participants are needed for reliable results. It factors in the expected effect size, natural variability, and desired confidence level — ensuring findings are scientifically meaningful and not due to chance.
• Each study was conducted over varying lengths of time according to a series of research questions—such as whether AG1 could measurably impact specific markers such as nutrient status, or microbiome composition in various populations from healthy individuals, active people to those with occasional gut issues.

• The institution(s) that conducted the study analyzed and interpreted the results, and presented the findings to us. Given the volume and complexity of biomarker and microbiome data, we also partnered with advanced data science teams to ensure robust and accurate interpretation.
• The data and research study design underwent strict scrutiny, not only from third-party scientists and statisticians, but also from our internal AG1 team including regulatory, research and legal teams.
• Together, we identified the most meaningful outcomes on the formula as a whole—that shaped the development and launch of AG1 Next Gen, and that continue to inform how we communicate the science behind our products.

• We are committed to advancing scientific research through a level of integrity that goes well beyond the basic requirements for publication. The next phase of the publishing process starts with submitting abstracts – another word for summaries – to annual conferences.
• Upon acceptance, these submissions arechosen for poster (a visual summary of research findings) or an oral presentation. Abstracts are typically published post-symposium, and the timing can vary depending on the scientific meeting.
• We’ve recently had abstracts accepted and presented at several national scientific conferences, including:
  • 2025 American Physiology Summit (April 24–27)
  • 2025 American Society of Nutrition (May 31–June 3)
  • 2025 American Society of Microbiology Annual Conference (June 19–23)
  • 2025 The International Society of Sports Nutrition Annual International Conference (June 23-25)
  • And more.

• AG1 is preparing full manuscripts containing more data from all four trials, which will be submitted to peer-reviewed journals over the coming months for publication.

The process of undertaking a trial, analyzing the results, and publishing them can take years. But we know it’s worth the wait, because we’re committed to advancing science—not just for the sake of innovation, but to contribute meaningfully to advancing the science of nutrition and the microbiome forward.

AG1 Next Gen has been studied across multiple clinical trials, consistently demonstrating its effectiveness in closing common nutrient gaps and supporting gut health.

• Triple-blind, randomized, placebo-controlled trial (105 healthy adults who consumed a Standard American Diet) measuring nutrient biomarkers and microbiome changes.
• Double-blind, placebo-controlled crossover trial (20 highly active healthy adults) assessing nutrient gaps and microbiome changes.
• Double-blind, placebo-controlled crossover trial (24 healthy adults with occasional digestive discomfort) assessing nutrient gaps and microbiome changes.
• Double-blind, placebo-controlled crossover trial (16 healthy adults) measuring nutrient absorption and bioavailability.

At a high-level, AG1 Next Gen was clinically shown to close common nutrient gaps—areas where the average diet may fall short—and support gut health, two critical factors for overall health, energy, and daily function. These results were consistent across multiple gold-standard clinical trials studying a range of lifestyles, including healthy adults who ate a Standard American Diet, highly active adults, and healthy adults experiencing occasional digest discomfort.

After these studies concluded, the data and research underwent strict scrutiny from third-party scientists and statisticians, as well as our internal AG1 regulatory, research and legal teams. Together, we identified the most meaningful and measurable insights that shaped the development and launch of AG1 Next Gen. You can learn more on our Research page.

A gold standard clinical trial refers to a randomized, double-blind, placebo-controlled study. These types of trials are considered the highest-quality study design in scientific research because it minimizes bias and ensures reliable, scientifically valid results.

Several AG1 reviews and studies have already been published in leading peer-reviewed journals, including Nutrients, Frontiers, Nutraceuticals, and the Journal of Functional Foods. In addition to publishing the methodology and results on our site, manuscripts covering results from the latest research studies on AG1 Next Gen are being prepared and will be submitted to peer-reviewed journals. The review process for publication is rigorous, and can take time given the evaluation includes an in-depth evaluation by a panel of independent experts. You can learn more about the clinical research lifecycle on our Research page.

In addition to the key findings that have already been shared, we are committed to advancing scientific research through a level of integrity that goes well beyond the basic requirements for publication. The next phase of the publishing process starts with submitting abstracts – another word for summaries – to annual conferences.

We’ve recently had abstracts accepted at several national scientific conferences, including:

• 2025 American Physiology Summit (April 24–27)
• 2025 American Society of Nutrition (May 31–June 3)
• 2025 American Society of Microbiology Annual Conference (June 19–23)
• 2025 The International Society of Sports Nutrition Annual International Conference (June 23-25)
• And more

We’re proud to hold some of the highest standards in the supplement category. Since 2010, we have earned the trust of millions of people around the world with our relentless approach to quality, efficacy, and safety.

This includes rigorously testing AG1 for hundreds of contaminants, including heavy metals, allergens, and over 500 herbicides and pesticides. Through NSF Certified for Sport®, an independent third-party program that certifies dietary supplements are free from substances banned by major sporting organizations, we also test for over 280 banned substances, including stimulants, narcotics, diuretics, and masking agents.

You can read more about our standards and processes here.